| Code | CSB-MP008646HU(F2) |
| Abbreviation | Recombinant Human FGFR3 protein, partial (Active) |
| MSDS | |
| Size | $114 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
FGFR3 dysregulation drives oncogenesis in bladder carcinoma, multiple myeloma, and skeletal dysplasia syndromes, making quantitative assessment of receptor-ligand and receptor-antibody interactions critical for therapeutic development. This mammalian-expressed construct spanning residues 127–377 of isoform 2 captures the extracellular ligand-binding domain with native glycosylation patterns that preserve conformational epitopes, as demonstrated by functional ELISA binding to an anti-FGFR3 recombinant antibody with an EC50 of 3.364–3.827 ng/mL. The validated binding activity supports use in competitive inhibition assays for blocking antibody screening, therapeutic antibody epitope mapping, and small-molecule inhibitor discovery campaigns targeting FGFR3-driven malignancies. Dual purity verification by SDS-PAGE and SEC-HPLC (both >95%) combined with endotoxin levels below 1.0 EU/μg meets the quality thresholds commonly required for surface plasmon resonance affinity characterization and biolayer interferometry kinetic studies.
There are currently no reviews for this product.